Patrick Reid
11Patents
4h-index
43Co-inventors
52Inventor score
Filing activity: Sep 2, 2013 → Mar 3, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9308236B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 24 | Active |
| US10711268B2 | Method for producing peptide library, peptide library, and screening method | Chemistry; Metallurgy | 14 | Active |
| US9879046B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 13 | Active |
| US9850283B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Physics | 9 | Active |
| US10328143B2 | Hemagglutinin-binding peptide | Chemistry; Metallurgy | 0 | Active |
| US9815867B2 | Peptide for inhibiting vascular endothelial growth factor receptor | Human Necessities | 0 | Active |
| US10745692B2 | Production method for charged non-protein amino acid-containing peptide | Emerging Cross-Sectional Technologies | 0 | Active |
| US11970694B2 | Rapid display method in translational synthesis of peptide | Chemistry; Metallurgy | 0 | Active |
| US10632187B2 | Hemagglutinin-binding peptide | Chemistry; Metallurgy | 0 | Active |
| US12209144B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | Human Necessities | 0 | Active |
| US11149066B2 | Thrombospondin 1-binding peptide | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.